In PD patients, peptides derived from two different regions of α-synuclein (i.e., Y39, which is situated in close proximity to known α-synuclein point mutations, and S129) act as antigenic epitopes and stimulate an immune response by CD4+ or CD8+T cells [58]. This evidence concerns the gene CD8A and Parkinson disease.